Targeting cerebrovascular Rho-kinase in stroke

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 12, 2008, Pages 1547-1564

  Shin, Hwa Kyoung ^a   Salomone, Salvatore ^b   Ayata, Cenk ^c  

^a Pusan National University   (South Korea)

^b UNIVERSITY OF CATANIA   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cerebral ischemia; Fasudil; Rho; Rho associated kinase; Stroke

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANESTHETIC AGENT; FASUDIL; HYDROXYFASUDIL; RHO KINASE; RHO KINASE INHIBITOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN REGION; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FOREBRAIN; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; VASODILATATION;

DRUG DESIGN; HUMANS; RHO-ASSOCIATED KINASES; STROKE; UP-REGULATION;

EID: 57549117258     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802539244     Document Type: Review

References (197)

1. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273(5272):245-8
2. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22(1):32-9
3. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Embo J 1996;15(9):2208-16
4. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290(3):C661-8
5. Chrissobolis S, Sobey CG. Recent evidence for an involvement of rho-kinase in cerebral vascular disease. Stroke 2006;37(8):2174-80
6. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 2006;27(2):97-104
7. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005;25(9):1767-75
8. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995;270(49):29051-4
9. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROKα is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16(10):5313-27
10. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. Embo J 1996;15(8):1885-93
11. Nobes C, Hall A. Regulation and function of the Rho subfamily of small GTPases. Curr Opin Genet Dev 1994;4(1):77-81
12. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4(6):446-56
13. Amano M, Chihara K, Nakamura N, et al. The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity. J Biol Chem 1999;274(45):32418-24
14. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261(1):44-51
15. Feng J, Ito M, Kureishi Y, et al. Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem 1999;274(6):3744-52
16. Feng J, Ito M, Ichikawa K, et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274(52):37385-90
17. Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001;3(4):346-52
18. Coleman ML, Sahai EA, Yeo M, et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001;3(4):339-45
19. Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lest 1996;392(2):189-93
20. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271(34):20246-9
21. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999;147(5):1023-38
22. Matsui T, Maeda M, Doi Y, et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998;140(3):647-57
23. Ohashi K, Nagata K, Maekawa M, et al. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 2000;275(5):3577-82
24. Sumi T, Matsumoto K, Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 2001;276(1):670-6
25. Chevrier V, Piel M, Collomb N, et al. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol 2002;157(5):807-17
26. Miyagi Y, Carpenter RC, Meguro T, et al. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000;93(3):471-6
27. Hashimoto R, Nakamura Y, Kosako H, et al. Distribution of Rho-kinase in the bovine brain. Biochem Biophys Res Commun 1999;263(2):575-9
28. Wei L, Roberts W, Wang L, et al. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 2001;128(15):2953-62
29. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168(6):941-53
30. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23(14):5043-55
31. Zhang YM, Bo J, Taffet GE, et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. Faseb J 2006;20(7):916-25
32. Rikitake Y, Oyama N, Wang CY, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005;112(19):2959-65
33. Thumkeo D, Shimizu Y, Sakamoto S, et al. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 2005;10(8):25-34
34. Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008;118(5):1632-44
35. Schueller O, Tong W, Ferkany J, Sweetnam P. Selective ROCK 2 inhibition attenuates arterial plaque formation in an ApoE knockout mouse model [abstract 1216]. Circulation 2006;114: II 228
36. Velasco G, Armstrong C, Morrice N, et al. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett 2002;527(1-3):101-4
37. Kitazawa T, Eto M, Woodsome TP, Khalequzzaman M. Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle. J Physiol 2003;546(Pt 3):879-89
38. Kureishi Y, Kobayashi S, Amano M, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997;272(19):12257-60
39. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83(4):1325-58
40. Gong MC, Fujihara H, Somlyo AV, Somlyo AP. Translocation of rhoA associated with Ca2+ sensitization of smooth muscle. J Biol Chem 1997;272(16):10704-9
41. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389(6654):990-4
42. Bussemaker E, Pistrosch F, Forster S, et al. Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am J Physiol 2007;293(1):H541-7
43. Nagumo H, Sasaki Y, Ono Y, et al. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 2000;278(1):C57-65
44. Takayasu M, Dacey RG Jr. Effects of HA1077, a novel calciumantagonistic spasmolytic agent on intracerebral arterioles of rats. Acta Neurochir (Wien) 1990;103(1-2):67-70
45. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241(3):1033-40
46. Asano T, Suzuki T, Tsuchiya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989;98(4):1091-100
47. Gokina NI, Park KM, McElroy-Yaggy K, Osol G. Effects of Rho kinase inhibition on cerebra] artery myogenic tone and reactivity. J Appl Physiol 2005;98(5):1940-8
48. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285(5429):895-8
49. Cipolla MJ, Gokina NI, Osol G. Pressure-induced actin polymerization in vascular smooth muscle as a mechanism underlying myogenic behavior. FASEB J 2002;16(1):72-6
50. Sasaki Y, Sasaki Y, Kanno K, Hidaka H. Disorganization by calcium antagonists of actin microfilament in aortic smooth muscle cells. Am J Physiol 1987;253(1 Pt 1):C71-8
51. Negoro N, Hoshiga M, Seto M, et al. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun 1999;262(1):211-5
52. Sawada N, Itoh H, Ueyama K, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000;101(17):2030-3
53. Wamhoff BR, Bowles DK, McDonald OG, et al. L-type voltage-gated Ca2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-dependent mechanism. Circ Res 2004;95(4):406-14
54. Napoli C, De Nigris F, Williams-Ignarro S, et al. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006;15(4):265-79
55. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci 2004;27(5):283-9
56. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95(15):8880-5
57. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106(1):57-62
58. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273(37):24266-71
59. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005;36(10):2251-7
60. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002;22(24):8467-77
61. Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004;24(10):1842-7
62. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399(6736):597-601
63. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 2002;39(4-5):187-99
64. Kahles T, Luedike P, Endres M, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007;38(11):3000-6
65. Wojciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci 2001;114(Pt7):1343-55
66. McKenzie JA, Ridley AJ. Roles of Rho/ROCK and MLCK in TNF-α-induced changes in endothelial morphology and permeability. J Cell Physiol 2007;213(1):221-8
67. Hyvelin JM, Howell K, Nichol A, et al. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97(2):185-91
68. Yin L, Morishige K, Takahashi T, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol Cancer Ther 2007;6(5):1517-25
69. Wahl S, Barth H, Ciossek T, et al. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol 2000;149(2):263-70
70. Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003;23(4):1416-23
71. Katoh H, Aoki J, Ichikawa A, Negishi M. p160 RhoA-binding kinase ROKα induces neurite retraction. J Biol Chem 1998;273(5):2489-92
72. Borisoff JF, Chan CC, Hiebert GW, et al. Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci 2003;22(3):405-16
73. Da Silva JS, Medina M, Zuliani C, et al. RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 2003;162(7):1267-79
74. Threadgill R, Bobb K, Ghosh A. Regulation of dendritic growth and remodeling by Rho, Rac, and Cdc42. Neuron 1997;19(3):625-34
75. Bito H, Furuyashiki T, Ishihara H, et al. A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron 2000;26(2):431-41
76. Jalink K, Van Corven EJ, Hengeveld T, et al. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol 1994;126(3):801-10
77. Lehmann M, Fournier A, Selles-Navarro I, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999;19(17):7537-47
78. Lingor P, Tonges L, Pieper N, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008;131(Pt 1):250-63
79. Kosako H, Amano M, Yanagida M, et al. Phosphorylaticn of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. J Biol Chem 1997;272(16):10333-6
80. Piccoli G, Rutishauser U, Bruses JL. N-cadherin juxtamembrane domain modulates voltage-gated Ca2+ current via RhoA GTPase and Rho-associated kinase. J Neurosci 2004;24(48):10918-23
81. Norenberg W, Hofmann F, Illes P, et al. Rundown of somatodendritic N-methyl-D-aspartate (NMDA) receptor channels in rat hippocampal neurones: evidence for a role of the small GTPase RhoA. Br J Pharmacol 1999;127(5):1060-3
82. Nakazawa T, Kuriu T, Tezuka T, et al. Regulation of dendritic spine morphology by an NMDA receptor-associated Rho GTPase-activating protein, p250GAP. J Neurochem 2008;105(4):1384-93
83. Nakazawa T, Watabe AM, Tezuka T, et al. p250GAP, a novel brain-enriched GTPase-activating protein for Rho family GTPases, is involved in the N-methyl-D-aspartate receptor signaling. Mol Biol Cell 2003;14(7):2921-34
84. Holtje M, Hoffmann A, Hofmann F, et al. Role of Rho GTPase in astrocyte morphology and migratory response during in vitro wound healing. J Neurochem 2005;95(5):1237-48
85. Abe K, Misawa M. Astrocyte stellation induced by Rho kinase inhibitors in culture. Brain Res Dev Brain Res 2003;143(1):99-104
86. Chan CC, Wong AK, Liu J, et al. ROCK inhibition with Y27632 activates astrocytes and increases their expression of neurite growth-inhibitory chondroitin sulfate proteoglycans. Glia 2007;55(4):369-84
87. Niggli V. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett 1999;445(1):69-72
88. Miyata K, Shimokawa H, Kandabashi T, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo Arterioscler Thromb Vasc Biol 2000;20(11):2351-8
89. Arai M, Sasaki Y, Nozawa R. Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol 1993;46(8):1487-90
90. Worthylake RA, Burridge K. RhoA and ROCK promote migration by limiting membrane protrusions. J Biol Chem 2003;278(15):13578-84
91. Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 1999;80(1):41-8
92. Hitomi A, Satoh S, Ikegaki I, et al. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci 2000;67(16):1929-39
93. Ono A, Westein E, Hsiao S, et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood 2008;112(1):90-9
94. Essler M, Retzer M, Bauer M, et al. Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. Ann NY Acad Sci 2000;905:282-6
95. Klages B, Brandt U, Simon MI, et al. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999;144(4):745-54
96. Missy K, Plantavid M, Pacaud P, et al. Rho-kinase is involved in the sustained phosphorylation of myosin and the irreversible platelet aggregation induced by PAR1 activating peptide. Thromb Haemost 2001;85(3):514-20
97. Suzuki Y, Yamamoto M, Wada H, et al. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 1999;93(10):3408-17
98. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 2002;277(49):47588-95
99. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. Faseb J 2001;15(6):1062-4
100. Seasholtz TM, Zhang T, Morissette MR, et al. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27Kip1 expression in the vasculature of hypertensive rats. Circ Res 2001;89(6):488-95
101. Moriki N, Ito M, Seko T, et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004;27(4):263-70
102. Seko T, Ito M, Kureishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003;92(4):411-8
103. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther 2004;309(3):1011-9
104. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circ Res 2001;88(8):774-9
105. Kitazono T, Ago T, Kamouchi M, et al. Increased activity of calcium channels and Rho-associated kinase in the basilar artery during chronic hypertension in vivo J Hypertens 2002;20(5):879-84
106. Jarajapu YP, Knot HJ. Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension. Am J Physiol Heart Circ Physiol 2005;289(5):H1917-22
107. Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001;38(6):1307-10
108. Faraci FM, Lamping KG, Modrick ML, et al. Cerebral vascular effects of angiotensin II: new insights from genetic models. J Cereb Blood Flow Metab 2006;26(4):449-55
109. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93(8):767-75
110. Sandu OA, Ragolia L, Begum N. Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 2000;49(12):2178-89
111. Miao L, Calvert JW, Tang J, Zhang JH. Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci 2002;71(10):1175-85
112. Didion SP, Lynch CM, Baumbach GL, Faraci FM. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes. Stroke 2005;36(2):342-7
113. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005;111(24):3261-8
114. Shah DI, Singh M. Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol Cell Biochem 2006;283(1-2):191-9
115. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004;101(24):9121-6
116. Iwasaki H, Okamoto R, Kato S, et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-κB activation in bovine aortic endothelial cells. Atherosclerosis 2008;196(1):22-8
117. Zhu Y, Liao HL, Niu XL, et al. Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation. Biochim Biophys Acta 2003;1635(2-3):117-26
118. Morikage N, Kishi H, Sato M, et al. Cholesterol primes vascular smooth muscle to induce Ca2 sensitization mediated by a sphingosylphosphorylcholine-Rho-kinase pathway: possible role for membrane raft. Circ Res 2006;99(3):299-306
119. Bolz SS, Galle J, Derwand R, et al. Oxidized LDL increases the sensitivity of the contractile apparatus in isolated resistance arteries for Ca2+ via a rho- and rho kinase-dependent mechanism. Circulation 2000;102(19):2402-10
120. Steioff K, Rutten H, Busch AE, et al. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice. Eur J Pharmacol 2005;512(2-3):247-9
121. Nohria A, Grunert ME, Rikitake Y, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006;99(12):1426-32
122. Erdo F, Trapp T, Mies G, Hossmann KA. Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice. Acta Neuropathol (Berl) 2004;107(2):127-36
123. Trapp T, Olah L, Holker I, et al. GTPase RhoB: an early predictor of neuronal death after transient focal ischemia in mice. Mol Cell Neurosci 2001;17(5):883-94
124. Brabeck C, Mittelbronn M, Bekure K, et al. Effect of focal cerebral infarctions on lesional RhoA and RhoB expression. Arch Neurol 2003;60(9):1245-9
125. Shin HK, Salomone S, Potts EM, et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2007;27(5):998-1009
126. Yamashita K, Kotani Y, Nakajima Y, et al. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007;1154:215-24
127. Yagita Y, Kitagawa K, Sasaki T, et al. Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res 2007;85(11):2460-9
128. Vedernikov YP, Graser T, Leisner H, Tiedt N. Effect of hypoxia on endothelium-dependent relaxation of porcine coronary arteries and veins. Biomed Biochim Acta 1991;50(3):257-63
129. Ikenoya M, Hidaka H, Hosoya T, et al. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem 2002;81(1):9-16
130. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999;43(4):1029-39
131. Satoh S, Toshima Y, Hitomi A, et al. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 2008;1193:102-8
132. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000;57(5):976-83
133. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93(2-3):225-32
134. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28(6):296-302
135. Doe C, Bentley R, Behm DJ, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007;320(1):89-98
136. Shibuya M, Suzuki Y, Takayasu M, et al. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs. Acta Neurochir (Wien) 1988;90(1-2):53-59
137. Takayasu M, Suzuki Y, Shibuya M, et al. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg 1986;65(1):80-5
138. Ohtaki M, Tranmer B. Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877. Stroke 1994;25(6):1234-9; discussion 40
139. Tsuchiya M, Sako K, Yonemasu Y, Asano T. The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats. Exp Brain Res 1993;97(2):233-8
140. Huang L, He Z, Guo L, Wang H. Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of Rho-kinase. Cell Mol Neurobiol 2008;28(5):757-68
141. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiolgoy. Circ Res 2006;98(3):322-34
142. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 2005;3(3):441-51
143. Shin HK, Dunn AK, Jones PB, et al. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 2006;26(8):1018-30
144. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001;32(4):980-6
145. Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000;101(3):264-9
146. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14(4):361-6
147. Moers A, Nieswandt B, Massberg S, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003;9(11):1418-22
148. Moers A, Wettschureck N, Offermanns S. G13-mediated signaling as a potential target for antiplatelet drugs. Drug News Perspect 2004;17(8):493-8
149. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 2001;69(12):1441-53
150. Satoh S, Ikegaki I, Suzuki Y, et al. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br J Pharmacol 1996;118(7):1592-6
151. Ayata C, Ropper AH. Ischaemic brain oedema. J Clin Neurosci 2002;9(2):113-24
152. Jeon S, Kim S, Park JB, et al. RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate. J Biol Chem 2002;277(19):16576-84
153. Kitaoka Y, Kitaoka Y, Kumai T, et al. Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res 2004;1018(1):111-8
154. Maiese K, Wagner J, Boccone L. Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade. Neurosci Len 1994;166(1):43-7
155. Semenova MM, Maki-Hokkonen AM, Cao J, et al. Rho mediates calcium-dependent activation of p38α and subsequent excitotoxic cell death. Nat Neurosci 2007;10(4):436-43
156. Nishio Y, Koda M, Kitajo K, et al. Delayed treatment with Rho-kinase inhibitor does not enhance axonal regeneration or functional recovery after spinal cord injury in rats. Exp Neurol 2006;200(2):392-7
157. Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22(15):6570-7
158. Sung JK, Miao L, Calvert JW, et al. A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res 2003;959(1):29-38
159. Hara M, Takayasu M, Watanabe K, et al. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg 2000;93(Suppl 1):94-101
160. Tanaka H, Yamashita T, Yachi K, et al. Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 2004;127(1):155-64
161. Lingor P, Teusch N, Schwarz K, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 2007;103(1):181-9
162. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev 2005;4(5):387-98
163. Lee JK, Kim JE, Sivula M, Strittmatter SM. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci 2004;24(27):6209-17
164. Wiessner C, Bareyre FM, Allegrini PR, et al. Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J Cereb Blood Flow Metab 2003;23(2):154-65
165. Schwab JM, Monnier PP, Schluesener HJ, et al. Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain. Arch Neurol 2005;62(10):1561-8
166. Satoh S, Toshima Y, Ikegaki I, et al. Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils. Brain Res 2007;1128(1):175-80
167. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76(4):571-7
168. Shibuya M, Hirai S, Seto M, et al. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005;238(1-2):31-9
169. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002;61(5):1684-95
170. Takeda K, Jin MB, Fujita M, et al. A novel inhibitor of Rho-associated protein kinase, Y-27632, ameliorates hepatic ischemia and reperfusion injury in rats. Surgery 2003;133(2):197-206
171. Takanashi Y, Ishida T, Kirchmeier MJ, et al. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. Neurol Med Chir (Tokyo) 2001;41(3):107-13; discussion 13-4
172. Takanashi Y, Ishida T, Meguro T, et al. Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 2001;48(4):894-900; discussion-1
173. Takanashi Y, Ishida T, Meguro T, et al. Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. J Clin Neurosci 2001;8(6):557-61
174. Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol pharm bull 2006;29(3):397-402
175. Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Inhibition of agonist-induced positive inotropy by a selective Rho-associated kinase inhibitor, Y-27632. J Pharmacol Sci 2003;92(4):424-7
176. Takahara A, Sugiyama A, Satoh Y, et al. Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol 2003;460(1):51-7
177. Hirooka Y. Adenovirus-mediated gene transfer into the brain stem to examine cardiovascular function: role of nitric oxide and Rho-kinase. Ping Biophys Mol Biol 2004;84(2-3):233-49
178. Sugiyama A, Yatomi Y, Takahara A, et al. Cardiac effects of a selective rho-associated kinase inhibitor, Y-27632, assessed in canine isolated, blood-perfused heart preparations. Jpn J Pharmacol 2002;88(3):359-61
179. Ito K, Hirooka Y, Sakai K, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 2003;92(12):1337-43
180. Shibuya M, Suzuki Y, Sugita K, et al. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid
181. Suzuki Y, Shibuya M, Satoh S, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007; 68(2):126-31; discussion 31-2
182. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002;40(5):751-61
183. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46(10):1803-11
184. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 2003;93(9):884-8
185. Mita S, Kobayashi N, Yoshida K, et al. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 2005;23(1):87-96
186. Recommendations for standards regarding preclinical neuroptotective and restorative drug development. Stroke 1999;30(12):2752-8
187. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 2008;28(1):217-9
188. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-77
189. Fisher M. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34(6):1539-46
190. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32(7):1598-606
191. Kawamura S, Yasui N, Shirasawa M, Fukasawa H. AT-877, a Ca2+ antagonist, fails to reduce infarct size following rat middle-cerebral artery occlusion. Acts Neurol Scand 1993;88(4):269-72
192. Toshima Y, Satoh S, Ikegaki I, Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000;31(9):2245-50
193. Asano T, Ikegaki I, Satoh S, et al. Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain. Br J Pharmacol 1991;103(4):1935-8
194. Sako K, Tsuchiya M, Yonemasu Y, Asano T. HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats. Eur J Pharmacol 1991;209(1-2):39-43
195. Kanda T, Wakino S, Homma K, et al. Rho-kinase as a molecular target for insulin resistance and hypertension. Faseb J 2006;20(1):169-71
196. Satoh S, Suzuki Y, Ikegaki I, et al. The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs. Acta Neurochir (Wien) 1991;110(3-4):185-8
197. Nagata K, Kondoh Y, Satoh Y, et al. Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. Clin neuropharmacol 1993;16(6):501-10